Pulmonary Arterial Hypertension (PAH) Therapeutics - Global Strategic Business Report 2017: Focus on Endothelin Receptor Antagonist, Prostacyclin and Prostacyclin, PDE-5 Inhibitors & sGC Stimulator - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Pulmonary Arterial Hypertension (PAH) Therapeutics - Global Strategic Business Report" report to their offering.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.

This report analyzes the worldwide markets for Pulmonary Arterial Hypertension (PAH) Therapeutics in US$ Million.

The Global market is analyzed by the following Drug Class and Brands:

  • Endothelin Receptor Antagonist (Letairis/Volibris, Macitentan, Thelin, & Tracleer)
  • Prostacyclin and Prostacyclin Analogs (Epoprostenol/Veletri - , Flolan, Remodulin, Selexipag, Tyvaso, Ventavis, & Orenitram)
  • PDE-5 Inhibitors (Cialis/Adcirca, & Revatio)
  • Soluble Guanylate Cyclase (sGC) Stimulator (Riociguat)

The report profiles 31 companies including many key and niche players such as:

  • Actelion Pharmaceuticals Ltd (Switzerland)
  • Bayer AG (Germany)
  • Gilead Sciences, Inc. (US)
  • Pfizer, Inc. (US)
  • United Therapeutics Corporation (US)
  • Lung Biotechnology PBC (US)

Key Topics Covered:


  • Current & Future Analysis
  • PAH Drugs Market by Class
  • The PAH Classification
  • PH Patient Groupings as per World Health Organization
  • Classification of PAH patients as per New York Heart Association (NYHA)
  • Oral Therapies lead the Global PAH Therapeutics Market
  • Combination Therapy Favored over Monotherapy for PAH
  • Pediatric PAH
  • A Potential Market with Unmet Need
  • Inflammation: New Target for PAH Therapeutics
  • Aging Population & PAH


  • Leading Players
  • Leading Approved Drugs as Per Mode of Administration
  • Major Drug Brands by Class
  • Prostacyclin receptor agonist/ Prostacyclin Analogue
  • Flolan (Epoprostenol)
  • Ventavis (Iloprost)
  • Remodulin (Treprostinil)
  • Orenitram
  • Tyvaso
  • Uptravi (Selexipag)
  • Veletri® (Epoprostenol for Injection)
  • Phosphodiesterase 5 inhibitor
  • Revatio
  • Adcirca (Tadalafil)
  • Endothelin receptor antagonists (ERAs)
  • Opsumit
  • Tracleer (Bosentan)
  • Letairis (Ambrisentan)
  • Loss of Market exclusivity Tones Down Growth
  • Patent Expiry of Leading PAH Drugs
  • Opsumit & Uptravi: Game-changers for Actelion
  • Selexipag
  • Latest Entrant in PAH Therapeutics
  • United Therapeutics
  • A Major Player
  • Gilead Sciences
  • GlaxoSmithKline
  • Bayer


  • Pulmokine Investigates PDGF Receptor Pathway
  • Reata Pharmaceuticals Completes Phase 3 Study for Bardoxolone methyl
  • Eiger BioPharmaceuticals Commences Phase 2 Trials for Bestatin
  • Insmed Investigates INS 1009
  • LTT Bio-Pharma Focuses on LT-2004
  • Ascendis Investigates TransCon Treprostinil in a Phase I trial
  • Arena Initiates Phase II Trial for Ralinepeg,
  • TheraSilence nanoparticles Found to Reduce Pulmonary Arterial Thickness
  • CXA-10 to Undergo Phase II Study
  • Atu111 Undergoes Preclinical Trial for PH
  • RP5063
  • A NCE for PAH
  • SteadyMed to File NDA for Trevyent®
  • Pluristem's PLX-PAD
  • Sagene Pharmaceuticals, Inc.
  • Select PAH Therapeutics under Pipeline: 2016


  • Introduction
  • PAH Subgroups
  • PAH Therapeutics Timeline
  • Timeline for PAH Therapeutics
  • Causes and Development of PAH
  • Symptoms of PAH
  • Diagnosis of PAH
  • Identification of patients on clinical grounds
  • Detection of PAH
  • Evaluation and classification of PAH
  • Overview of Treatments for PAH
  • Treatments for PAH
  • Treatment Pathways in PAH
  • An Insight into PAH Drug Classes
  • Prostacyclin Analogs/Prostanoids
  • Endothelin Receptor Antagonists (ERAs)
  • Phosphodiesterase type 5 (PDE-5) Inhibitors
  • Soluble Guanylate Cyclase (sGC) Stimulator
  • PAH Therapies by Class
  • Prostacyclin Analogs/Prostanoids
  • Endothelin (ET-1) Receptor Antagonists
  • Phosphodiesterase-5 (PDE) Inhibitors
  • Soluble Guanylate Cyclase (sGC) Stimulators
  • Novel Therapies for PAH


  • Nippon Shinyaku Receives Marketing Approval for Uptravi
  • Actelion to Initiate Phase III Study for Pediatric Formulation of Opsumit
  • Actelion Announces USFDA Approval of Uptravi
  • Reata Pharmaceuticals' Bardoxolone Methyl Receives Orphan Drug Designation
  • Actelion Receives Approval for Opsumit from Japan's MHLW
  • Bayer Healthcare Receives Approval for Adempas from Japan's MHLW
  • Silence Therapeutics Develops Gene Toolkit for PAH Research
  • Arena Pharmaceuticals' APD811 Receives Orphan Drug Status for PAH Treatment
  • Bayer's Adempas Approved for Two Rare Types of PAH
  • Actelion's Opsumit Receives Approval from Australia's TGA


  • Arena Pharmaceuticals Initiates Phase 2 Clinical Trial for Ralinepag
  • Gilead Reports Top-Line Phase 2 Results for GS-4997 ( Selonsertib) in Pulmonary Arterial Hypertension (PAH)
  • Gilead Sciences Accelerates its PAH Portfolio
  • Mallinckrodt Pharmaceuticals Acquires Ikaria
  • Supernus Pharmaceuticals Receives US$2 million Milestone Payment from United Therapeutics
  • Vectura Group plc Acquires Activaero GmbH
  • Mast Therapeutics Completes Acquisition of Aires Pharmaceuticals



Total Companies Profiled: 31 (including Divisions/Subsidiaries 33)

  • The United States (18)
  • Japan (3)
  • Europe (10)
  • France (1)
  • Germany (3)
  • The United Kingdom (3)
  • Rest of Europe (3)
  • Asia-Pacific (Excluding Japan) (1)
  • Middle East (1)

For more information about this report visit http://www.researchandmarkets.com/research/slmnsz/pulmonary


Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Cardiovascular Drugs


Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Cardiovascular Drugs